Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE

Blood blood.2024024667.

https://doi.org/10.1182/blood.2024024667

Published: 2024

Includes: Supplemental data

Journal Articles

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Blood (2023) 142 (Supplement 1): 202.

https://doi.org/10.1182/blood-2023-174289

Published: 2023

Journal Articles

Acquired Mutations in Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) That Progressed in the ALPINE Study

Jennifer R. Brown, Jessica Li, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Luqui Qiu, Vanitha Ramakrishnan, Ruiqi Huang, Yang Shi, Adam Idoine, Tommi Salmi, Aileen Cleary Cohen, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 1890.

https://doi.org/10.1182/blood-2023-173547

Published: 2023

Journal Articles

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Ramon Garcia-Sanz, Roger Owen, Wojciech Jurczak, Meletios A. Dimopoulos, Helen McCarthy, Gavin Cull, Stephen Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cleary Cohen, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2023-174294

Published: 2023

Journal Articles

Broad Superiority of Zanubrutinib (Zanu) Over Bendamustine + Rituximab (BR) Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p)

Vanitha Ramakrishnan, Linlin Xu, Jason C. Paik, Carol Marimpietri, Eric Shen, Xiaoxi Dong, Jessica Li, Andreas Agathangelidis, Tian Tian, Aileen Cleary Cohen, Tadeusz Robak, Constantine S. Tam, Paolo Ghia, Andrew Rawstron, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 1902.

https://doi.org/10.1182/blood-2023-174543

Published: 2023

Journal Articles

Similar Efficacy of Ibrutinib Arms across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

Mazyar Shadman, Alessandra Tedeschi, Leyla Mohseninejad, Keri Yang, Nicole Lamanna, Sheng Xu, Aileen Cleary Cohen, Swetha Challagulla, Mei Xue, Rhys Williams, Susan M. O'Brien, Jennifer R. Brown, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 4655.

https://doi.org/10.1182/blood-2023-179222

Published: 2023

Journal Articles

A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor (BTKi) Zanubrutinib in Patients with Waldenström Macroglobulinemia (WM)

Edwin C. Kingsley, Shannon Fabre, Motohisa Takai, Aileen Cleary Cohen, Jingjing Schneider, Jessica Li, James D'Olimpio

Blood (2023) 142 (Supplement 1): 6171.

https://doi.org/10.1182/blood-2023-172881

Published: 2023

Journal Articles

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Blood (2023) 142 (Supplement 1): 6510.

https://doi.org/10.1182/blood-2023-180161

Published: 2023

Journal Articles

Development of Hypertension and Atrial Fibrillation Following Diagnosis of B-Cell Malignancies - a Retrospective Analysis of US Marketscan Insurance Claims Database

Lili Zhou, Binglin Yue, Soraya Azmi, Meng Zhang, Aileen Cleary Cohen

Blood (2022) 140 (Supplement 1): 12377–12378.

https://doi.org/10.1182/blood-2022-167596

Published: 2022

Journal Articles

Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results,

Norman J. Lacayo, MD, Todd A. Alonzo, PhD, Urte Gayko, Ph.D., Matt Westfall, Ph.D., Norman Purvis, Ph.D., Santosh Putta, Ph.D., James Hackett, Ph.D., Aileen Cleary Cohen, MD, PhD, Robert B. Gerbing, M.A., Gary V Dahl, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, Ph.D.

Blood (2011) 118 (21): 3544.

https://doi.org/10.1182/blood.V118.21.3544.3544

Published: 2011

Journal Articles

Single Cell Network Profiling (SCNP) Reveals Age-and Disease-Based Heterogeneity in Healthy Individuals and in Patients with Low Risk (LR) Myelodysplastic Syndrome (MDS)

Aileen Cleary Cohen, MD, PhD, Ying-Wen Huang, MS, Alessandra Cesano, M.D., Ph.D., Rachael E. Hawtin, Ph.D., Jodi R. Ware, PharmD, Bishmaraj Arulrajah, B.S., Steven M. Kornblau, MD

Blood (2011) 118 (21): 2788.

https://doi.org/10.1182/blood.V118.21.2788.2788

Published: 2011

Journal Articles

Cost Burden Analysis of Ineffective Induction Chemotherapy in Elderly Patients with AML.

Aileen Cleary Cohen, MD, PhD, Nancy Davidson, JD, Jason Scharf, MBA, Derek Middlebrook, MBA

Blood (2009) 114 (22): 4531.

https://doi.org/10.1182/blood.V114.22.4531.4531

Published: 2009

Journal Articles

FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations.

M. D. Minden, MD, PhD, Steven M. Kornblau, MD, David B. Rosen, PhD, Aileen Cleary Cohen, MD, PhD, Urte Gayko, PhD, Santosh Putta, PhD, John Woronicz, PhD, Wendy J. Fantl, PhD, Alessandra Cesano, MD, PhD

Blood (2009) 114 (22): 1588.

https://doi.org/10.1182/blood.V114.22.1588.1588

Published: 2009

Journal Articles

Single Cell Network Profiling as a Tool to Identify AML Chemotherapy Resistant Cell Phenotypes Under In Vivo Therapeutic Pressure.

Alessandra Cesano, MD, PhD, John Woronicz, PhD, Aileen Cleary Cohen, MD, PhD, Todd Covey, Santosh Putta, PhD, Urte Gayko, PhD, Wendy J. Fantl, PhD, S.M. Kornblau, M.D.

Blood (2009) 114 (22): 397.

https://doi.org/10.1182/blood.V114.22.397.397

Published: 2009

Journal Articles

High Level Phosphatase Activity Revealed in Chronic Lymphocytic Leukemia Cells That Use Mutated Immunoglobulin Heavy Chain Variable Region Genes and Lack High-Level Expression of the Zeta-Associated Protein 70 (ZAP-70).

Wendy J. Fantl, PhD, Rolla L. Yafawi, BS, Santosh K. Putta, PhD, Ying-Wen Huang, MS, Helen L. Francis-Lang, PhD, Rassenti Z. Laura, PhD, Aileen Cleary Cohen, MD, PhD, Thomas J. Kipps, MD, PhD

Blood (2007) 110 (11): 743.

https://doi.org/10.1182/blood.V110.11.743.743

Published: 2007

NARROW

Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Acquired Mutations in Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) That Progressed in the ALPINE Study

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Broad Superiority of Zanubrutinib (Zanu) Over Bendamustine + Rituximab (BR) Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p)

Similar Efficacy of Ibrutinib Arms across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor (BTKi) Zanubrutinib in Patients with Waldenström Macroglobulinemia (WM)

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Development of Hypertension and Atrial Fibrillation Following Diagnosis of B-Cell Malignancies - a Retrospective Analysis of US Marketscan Insurance Claims Database

Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results,

Single Cell Network Profiling (SCNP) Reveals Age-and Disease-Based Heterogeneity in Healthy Individuals and in Patients with Low Risk (LR) Myelodysplastic Syndrome (MDS)

Cost Burden Analysis of Ineffective Induction Chemotherapy in Elderly Patients with AML.

FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations.

Single Cell Network Profiling as a Tool to Identify AML Chemotherapy Resistant Cell Phenotypes Under In Vivo Therapeutic Pressure.

High Level Phosphatase Activity Revealed in Chronic Lymphocytic Leukemia Cells That Use Mutated Immunoglobulin Heavy Chain Variable Region Genes and Lack High-Level Expression of the Zeta-Associated Protein 70 (ZAP-70).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only